{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:12:10Z","timestamp":1776417130798,"version":"3.51.2"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,17]]},"DOI":"10.7759\/cureus.107208","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:17:13Z","timestamp":1776413833000},"source":"Crossref","is-referenced-by-count":0,"title":["Innovations in the Treatment of Antibiotic-Resistant Infections in Internal Medicine"],"prefix":"10.7759","author":[{"given":"Sofia","family":"Almeida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro M","family":"Neves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vital","family":"Da Silva Domingues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report. 2021. (2021). https:\/\/www.who.int\/publications\/i\/item\/9789240027336."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022, 399:629-55. 10.1016\/S0140-6736(21)02724-0","journal-title":"Lancet"},{"key":"ref3","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU\/EEA (EARS-Net) - Annual Epidemiological Report 2023. (2023). https.\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-eueea-ears-net-annual-epidemiological-report...."},{"key":"ref4","unstructured":"Infections and Resistance Antimicrobials. PPCIRA Priority Program Report 2021. (Article in Portuguese). (2021). https:\/\/www.dgs.pt\/programa-nacional-de-controlo-da-infeccao\/relatorios\/infecoes-e-resistencias-aos-antimicrobianos-2...."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul M","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, et al.. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect. 2022, 28:521-47. 10.1016\/j.cmi.2021.11.025","journal-title":"Clin Microbiol Infect"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma PD","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022, 75:187-212. 10.1093\/cid\/ciac268","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin D","year":"2016","unstructured":"van Duin D, Bonomo RA. Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations. Clin Infect Dis. 2016, 63:234-41. 10.1093\/cid\/ciw243","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00350-1","article-title":"Microbiology of meropenem-vaborbactam: a novel carbapenem beta-lactamase inhibitor combination for carbapenem-resistant Enterobacterales infections","volume":"9","author":"Bhowmick T","year":"2020","unstructured":"Bhowmick T, Weinstein MP. Microbiology of meropenem-vaborbactam: a novel carbapenem beta-lactamase inhibitor combination for carbapenem-resistant Enterobacterales infections. Infect Dis Ther. 2020, 9:757-67. 10.1007\/s40121-020-00350-1","journal-title":"Infect Dis Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam TF","year":"2016","unstructured":"Barlam TF, Cosgrove SE, Abbo LM, et al.. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016, 62:e51-77. 10.1093\/cid\/ciw118","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa389","article-title":"Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States","volume":"7","author":"Aslam S","year":"2020","unstructured":"Aslam S, Lampley E, Wooten D, Karris M, Benson C, Strathdee S, Schooley RT. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open Forum Infect Dis. 2020, 7:ofaa389. 10.1093\/ofid\/ofaa389","journal-title":"Open Forum Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200903-0363OC","article-title":"Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial","volume":"180","author":"Meisel C","year":"2009","unstructured":"Meisel C, Schefold JC, Pschowski R, et al.. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009, 180:640-8. 10.1164\/rccm.200903-0363OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12111590","article-title":"Evaluation of antibiotic resistance mechanisms in Gram-negative bacteria","volume":"12","author":"Gauba A","year":"2023","unstructured":"Gauba A, Rahman KM. Evaluation of antibiotic resistance mechanisms in Gram-negative bacteria. Antibiotics (Basel). 2023, 12:1590. 10.3390\/antibiotics12111590","journal-title":"Antibiotics (Basel)"},{"key":"ref13","unstructured":"Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge. Boletim Epidemiol\u00f3gico Observa\u00e7\u00f5es. (Article in Portuguese). (2023). https.\/\/www.insa.min-saude.pt\/artigo-publicado-no-boletim-epidemiologico-observacoes-destacado-no-index-das-revistas-...."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2019.1595161","article-title":"Decreasing methicillin-resistant Staphylococcus aureus (MRSA) infections is attributable to the disappearance of predominant MRSA ST239 clones, Shanghai, 2008-2017","volume":"8","author":"Dai Y","year":"2019","unstructured":"Dai Y, Liu J, Guo W, et al.. Decreasing methicillin-resistant Staphylococcus aureus (MRSA) infections is attributable to the disappearance of predominant MRSA ST239 clones, Shanghai, 2008-2017. Emerg Microbes Infect. 2019, 8:471-8. 10.1080\/22221751.2019.1595161","journal-title":"Emerg Microbes Infect"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01160-17","article-title":"Trends in antibiotic susceptibility in Staphylococcus aureus in Boston, Massachusetts, from 2000 to 2014","volume":"56","author":"Kanjilal S","year":"2017","unstructured":"Kanjilal S, Sater MRA, Thayer M, Lagoudas GK, Kim S, Blainey PC, Grad YH. Trends in antibiotic susceptibility in Staphylococcus aureus in Boston, Massachusetts, from 2000 to 2014. J Clin Microbiol. 2017, 56:e01160-17. 10.1128\/JCM.01160-17","journal-title":"J Clin Microbiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.11.023","article-title":"Changes in the rates and population structure of methicillin-resistant Staphylococcus aureus (MRSA) from bloodstream infections: a single-centre experience (2000-2015)","volume":"17","author":"Nikolaras GP","year":"2019","unstructured":"Nikolaras GP, Papaparaskevas J, Samarkos M, et al.. Changes in the rates and population structure of methicillin-resistant Staphylococcus aureus (MRSA) from bloodstream infections: a single-centre experience (2000-2015). J Glob Antimicrob Resist. 2019, 17:117-22. 10.1016\/j.jgar.2018.11.023","journal-title":"J Glob Antimicrob Resist"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.11.008","article-title":"Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)","volume":"30","author":"Paniagua-Garc\u00eda M","year":"2024","unstructured":"Paniagua-Garc\u00eda M, Bravo-Ferrer JM, P\u00e9rez-Galera S, et al.. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA). Clin Microbiol Infect. 2024, 30:223-30. 10.1016\/j.cmi.2023.11.008","journal-title":"Clin Microbiol Infect"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14100997","article-title":"New antibiotics for treating infections caused by multidrug-resistant bacteria","volume":"14","author":"Machado E","year":"2025","unstructured":"Machado E, Sousa JC. New antibiotics for treating infections caused by multidrug-resistant bacteria. Antibiotics (Basel). 2025, 14:997. 10.3390\/antibiotics14100997","journal-title":"Antibiotics (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti M","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y, et al.. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021, 21:226-40. 10.1016\/S1473-3099(20)30796-9","journal-title":"Lancet Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2025.100104","article-title":"Synergistic combinations of antimicrobial peptides and conventional antibiotics: a strategy to delay resistance emergence in World Health Organization priority bacteria","volume":"78","author":"Roque-Borda CA","year":"2026","unstructured":"Roque-Borda CA, Zhang Q, Nguyen TPT, et al.. Synergistic combinations of antimicrobial peptides and conventional antibiotics: a strategy to delay resistance emergence in World Health Organization priority bacteria. Pharmacol Rev. 2026, 78:100104. 10.1016\/j.pharmr.2025.100104","journal-title":"Pharmacol Rev"},{"key":"ref21","article-title":"Redefining Health Care: Creating Value-Based Competition on Results","author":"Porter ME","year":"2006","unstructured":"Porter ME, Teisberg EO. Redefining Health Care: Creating Value-Based Competition on Results. Harvard Business School Press, Boston, MA; 2006."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2018.07.034","article-title":"Participatory implementation of an antibiotic stewardship programme supported by an innovative surveillance and clinical decision-support system","volume":"100","author":"Sim\u00f5es AS","year":"2018","unstructured":"Sim\u00f5es AS, Maia MR, Greg\u00f3rio J, et al.. Participatory implementation of an antibiotic stewardship programme supported by an innovative surveillance and clinical decision-support system. J Hosp Infect. 2018, 100:257-64. 10.1016\/j.jhin.2018.07.034","journal-title":"J Hosp Infect"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-024-05027-y","article-title":"Artificial intelligence in antimicrobial stewardship: a systematic review and meta-analysis of predictive performance and diagnostic accuracy","volume":"44","author":"Pennisi F","year":"2025","unstructured":"Pennisi F, Pinto A, Ricciardi GE, et al.. Artificial intelligence in antimicrobial stewardship: a systematic review and meta-analysis of predictive performance and diagnostic accuracy. Eur J Clin Microbiol Infect Dis. 2025, 44:463-513. 10.1007\/s10096-024-05027-y","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1086\/670623","article-title":"Antimicrobial stewardship and automated pharmacy technology improve antibiotic appropriateness for community-acquired pneumonia","volume":"34","author":"Ostrowsky B","year":"2013","unstructured":"Ostrowsky B, Sharma S, DeFino M, et al.. Antimicrobial stewardship and automated pharmacy technology improve antibiotic appropriateness for community-acquired pneumonia. Infect Control Hosp Epidemiol. 2013, 34:566-72. 10.1086\/670623","journal-title":"Infect Control Hosp Epidemiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/467468-innovations-in-the-treatment-of-antibiotic-resistant-infections-in-internal-medicine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:17:18Z","timestamp":1776413838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/467468-innovations-in-the-treatment-of-antibiotic-resistant-infections-in-internal-medicine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.107208","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}